Prediction of site-specific pharmacologic therapy among newborns with neonatal opioid withdrawal syndrome
Authors:
- Mara G. CoyleMCMara G. Coyle
- Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network and the NIH Environmental Influences on Child Health Outcomes (ECHO) Program Institutional Development Awards States Pediatric Clinical Trials NetworENEunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network and the NIH Environmental Influences on Child Health Outcomes (ECHO) Program Institutional Development Awards States Pediatric Clinical Trials Networ
Open Access
- 15 October 2024
- journal article
- research article
- Published by Springer Nature in Journal of Perinatology
- Vol. 45 (4) , 465-472
Abstract
Objective To predict pharmacotherapy for NOWS based on factors available shortly after birth. Study design A multi-center, retrospective study of 1377 opioid exposed newborns between 2016 and 2017 dichotomized based on pharmacologic treatment (N = 665 treated, N = 712 not treated) was conducted. A multilevel mixed-effect logistic regression model that considered cluster effect from sites determined significant maternal and newborn factors associated with pharmacotherapy, which were combined in a nomogram to predict probability of treatment for infants at each participating site. Results Factors predictive of treatment were: no breastmilk (1.76, 1.30–2.39; p < 0.001), male sex (1.39, 1.05–1.83; p = 0.021), polysubstance exposure (1.53, 1.15–2.06; p = 0.004), inadequate prenatal care (1.51, 1.07–2.13; p < 0.018) and Methadone (6.08, 4.03–9.27; p < 0.001) or Buprenorphine (1.86, 1.29–2.69; p < 0.001). A site-specific nomogram provided the probability of treatment for individual newborns. Conclusion Six factors available shortly after birth can be combined to predict site-specific use of medication for NOWS. If confirmed, the nomogram may identify at-risk newborns.Keywords
This publication has 34 references indexed in Scilit:
- Conflating Race and Genetics Among Newborns With Neonatal Abstinence SyndromeJAMA Pediatrics, 2021
- Assessment of Racial and Ethnic Disparities in the Use of Medication to Treat Opioid Use Disorder Among Pregnant Women in MassachusettsJAMA Network Open, 2020
- Substance use disorders in pregnancy: clinical, ethical, and research imperatives of the opioid epidemic: a report of a joint workshop of the Society for Maternal-Fetal Medicine, American College of Obstetricians and Gynecologists, and American Society of Addiction MedicineAmerican Journal of Obstetrics and Gynecology, 2019
- Association of Rooming-in With Outcomes for Neonatal Abstinence SyndromeJAMA Pediatrics, 2018
- Maternal and infant outcomes following third trimester exposure to marijuana in opioid dependent pregnant women maintained on buprenorphineDrug and Alcohol Dependence, 2017
- Early Prediction Tool to Identify the Need for Pharmacotherapy in Infants at Risk of Neonatal Abstinence SyndromePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2017
- Rural and Urban Differences in Neonatal Abstinence Syndrome and Maternal Opioid Use, 2004 to 2013JAMA Pediatrics, 2017
- The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studiesInternational Journal of Surgery, 2014
- Epigenetic Variation in the Mu-Opioid Receptor Gene in Infants with Neonatal Abstinence SyndromeThe Journal of Pediatrics, 2014
- Are Male Neonates More Vulnerable to Neonatal Abstinence Syndrome Than Female Neonates?Gender Medicine, 2011